Evoke Pharma EPS - Earnings per Share 2012-2023 | EVOK
Evoke Pharma eps - earnings per share from 2012 to 2023. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Evoke Pharma Annual EPS |
| 2023 |
$-2.33 |
| 2022 |
$-2.62 |
| 2021 |
$-3.18 |
| 2020 |
$-6.24 |
| 2019 |
$-3.84 |
| 2018 |
$-5.52 |
| 2017 |
$-10.80 |
| 2016 |
$-13.81 |
| 2015 |
$-22.45 |
| 2014 |
$-26.41 |
| 2013 |
$-14.41 |
| 2012 |
$-21.49 |
| 2011 |
$-26.17 |
| Evoke Pharma Quarterly EPS |
| 2023-12-31 |
$-0.59 |
| 2023-09-30 |
$-0.51 |
| 2023-06-30 |
$-0.56 |
| 2023-03-31 |
$-0.67 |
| 2022-12-31 |
$-0.51 |
| 2022-09-30 |
$-0.60 |
| 2022-06-30 |
$-0.71 |
| 2022-03-31 |
$-0.80 |
| 2021-12-31 |
$-0.64 |
| 2021-09-30 |
$-0.73 |
| 2021-06-30 |
$-0.85 |
| 2021-03-31 |
$-0.96 |
| 2020-12-31 |
$-1.08 |
| 2020-09-30 |
$-0.96 |
| 2020-06-30 |
$-3.36 |
| 2020-03-31 |
$-0.84 |
| 2019-12-31 |
$-0.60 |
| 2019-09-30 |
$-0.84 |
| 2019-06-30 |
$-1.08 |
| 2019-03-31 |
$-1.32 |
| 2018-12-31 |
$-1.20 |
| 2018-09-30 |
$-1.08 |
| 2018-06-30 |
$-1.68 |
| 2018-03-31 |
$-1.56 |
| 2017-12-31 |
$-0.72 |
| 2017-09-30 |
$-4.08 |
| 2017-06-30 |
$-1.56 |
| 2017-03-31 |
$-4.44 |
| 2016-12-31 |
$0.00 |
| 2016-09-30 |
$-3.48 |
| 2016-06-30 |
$-4.92 |
| 2016-03-31 |
$-5.40 |
| 2015-12-31 |
$-4.20 |
| 2015-09-30 |
$-5.04 |
| 2015-06-30 |
$-6.24 |
| 2015-03-31 |
$-6.96 |
| 2014-12-31 |
$-5.88 |
| 2014-09-30 |
$-7.56 |
| 2014-06-30 |
$-7.08 |
| 2014-03-31 |
$-5.88 |
| 2013-12-31 |
$-1.68 |
| 2013-09-30 |
$-4.92 |
| 2013-06-30 |
$-2.52 |
| 2013-03-31 |
$-5.28 |
| 2012-12-31 |
$0.00 |
| 2012-09-30 |
$-5.16 |
| 2012-06-30 |
$0.00 |
| 2011-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.004B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
